Calorically restricted diets decrease PCSK9 in overweight adolescents

Nutr Metab Cardiovasc Dis. 2017 Apr;27(4):342-349. doi: 10.1016/j.numecd.2016.12.010. Epub 2017 Jan 3.

Abstract

Background and aims: Nutritional therapy is the first line approach to treatment of hyperlipidemia in childhood. Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key regulator of plasma cholesterol levels and a target of novel lipid-lowering pharmacotherapies. We examined the effects of an intensive nutritional intervention on PCSK9 levels in overweight adolescents with cardiovascular disease (CVD) risk factors.

Methods and results: Twenty seven obese and overweight adolescents with CVD risk factors were assigned to either a low fat or low glycemic load diet. During an 8-week "Intensive Phase," assigned meals were delivered to the home, and all participants received weekly in-person home nutrition counseling and phone calls. The subjects then underwent a 4-month "Maintenance Phase" without food provision and with no in-person contact. Anthropometric measurements, laboratory data, and serum PCSK9 protein levels were measured at baseline, 8 weeks, and 6 months. PCSK9 decreased by 16.5% at 8 weeks (201.2 ± 56.3 vs 165.6 ± 58.4 ng/mL; p < 0.001); PCSK9 levels returned to baseline levels at 6 months, after the Maintenance Phase. Change in PCSK9 was associated with change in fasting insulin, HOMA-IR, and AUC insulin, independent of weight loss.

Conclusions: PCSK9 decreased in youth participating in an intensive dietary intervention. Change in HOMA-IR was associated with change in PCSK9, independent of weight loss, suggesting an important relationship with insulin sensitivity. ClinicalTrials.gov Identifier: NCT01080339.

Keywords: Adolescents; Dyslipidemia; Nutritional Therapy; Obesity; PCSK9.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Age Factors
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Boston
  • Child
  • Counseling
  • Diet, Fat-Restricted*
  • Down-Regulation
  • Energy Intake*
  • Female
  • Glycemic Load*
  • Humans
  • Insulin / blood
  • Insulin Resistance
  • Male
  • Pediatric Obesity / diagnosis
  • Pediatric Obesity / diet therapy*
  • Pediatric Obesity / enzymology
  • Pediatric Obesity / physiopathology
  • Proprotein Convertase 9 / blood*
  • Time Factors
  • Treatment Outcome
  • Weight Loss

Substances

  • Biomarkers
  • Blood Glucose
  • Insulin
  • PCSK9 protein, human
  • Proprotein Convertase 9

Associated data

  • ClinicalTrials.gov/NCT01080339